Selected research
Industry Research
Kidney (Renal) Fibrosis Industry Research Report 2026
Market perspective
The global Kidney (Renal) Fibrosis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Kidney (Renal) Fibrosis market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Kidney (Renal) Fibrosis market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Kidney (Renal) Fibrosis market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Kidney (Renal) Fibrosis include Merck, Roche, Pfizer, ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, InterMune, Genzyme Corporation, Galectin Therapeutics and BioLine Rx Ltd. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Kidney (Renal) Fibrosis market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Kidney (Renal) Fibrosis.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Kidney (Renal) Fibrosis Market by Company
Merck
Roche
Pfizer
ProMetic Life-Sciences Inc.
La Jolla Pharmaceutical Company
InterMune
Genzyme Corporation
Galectin Therapeutics
BioLine Rx Ltd
Kidney (Renal) Fibrosis Segment by Type
Vasopeptidase Inhibitors
Angiotensin Converting enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Renin Inhibitors
Pirfenidone
Kidney (Renal) Fibrosis Segment by Application
Clinic
Hospital
Research Center
Kidney (Renal) Fibrosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney (Renal) Fibrosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney (Renal) Fibrosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney (Renal) Fibrosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Kidney (Renal) Fibrosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vasopeptidase Inhibitors
- Angiotensin Converting enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Renin Inhibitors
- Pirfenidone
Applications
- Clinic
- Hospital
- Research Center
Companies covered
- Merck
- Roche
- Pfizer
- ProMetic Life-Sciences Inc.
- La Jolla Pharmaceutical Company
- InterMune
- Genzyme Corporation
- Galectin Therapeutics
- BioLine Rx Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Kidney (Renal) Fibrosis by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vasopeptidase Inhibitors
- 2.2.3 Angiotensin Converting enzyme (ACE) Inhibitors
- 2.2.4 Angiotensin II Receptor Blockers (ARBs)
- 2.2.5 Renin Inhibitors
- 2.2.6 Pirfenidone
- 2.3 Kidney (Renal) Fibrosis by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Research Center
- 2.4 Assumptions and Limitations
3 Kidney (Renal) Fibrosis Breakdown Data by Type
- 3.1 Global Kidney (Renal) Fibrosis Historic Market Size by Type (2021-2026)
- 3.2 Global Kidney (Renal) Fibrosis Forecasted Market Size by Type (2027-2032)
4 Kidney (Renal) Fibrosis Breakdown Data by Application
- 4.1 Global Kidney (Renal) Fibrosis Historic Market Size by Application (2021-2026)
- 4.2 Global Kidney (Renal) Fibrosis Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Kidney (Renal) Fibrosis Market Perspective (2021-2032)
- 5.2 Global Kidney (Renal) Fibrosis Growth Trends by Region
- 5.2.1 Global Kidney (Renal) Fibrosis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Kidney (Renal) Fibrosis Historic Market Size by Region (2021-2026)
- 5.2.3 Kidney (Renal) Fibrosis Forecasted Market Size by Region (2027-2032)
- 5.3 Kidney (Renal) Fibrosis Market Dynamics
- 5.3.1 Kidney (Renal) Fibrosis Industry Trends
- 5.3.2 Kidney (Renal) Fibrosis Market Drivers
- 5.3.3 Kidney (Renal) Fibrosis Market Challenges
- 5.3.4 Kidney (Renal) Fibrosis Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Kidney (Renal) Fibrosis Players by Revenue
- 6.1.1 Global Top Kidney (Renal) Fibrosis Players by Revenue (2021-2026)
- 6.1.2 Global Kidney (Renal) Fibrosis Revenue Market Share by Players (2021-2026)
- 6.2 Global Kidney (Renal) Fibrosis Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Kidney (Renal) Fibrosis Head Office and Area Served
- 6.4 Global Kidney (Renal) Fibrosis Players, Product Type & Application
- 6.5 Global Kidney (Renal) Fibrosis Manufacturers Established Date
- 6.6 Global Kidney (Renal) Fibrosis Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Kidney (Renal) Fibrosis Market Size (2021-2032)
- 7.2 North America Kidney (Renal) Fibrosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Kidney (Renal) Fibrosis Market Size by Country (2021-2026)
- 7.4 North America Kidney (Renal) Fibrosis Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Kidney (Renal) Fibrosis Market Size (2021-2032)
- 8.2 Europe Kidney (Renal) Fibrosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Kidney (Renal) Fibrosis Market Size by Country (2021-2026)
- 8.4 Europe Kidney (Renal) Fibrosis Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Kidney (Renal) Fibrosis Market Size (2021-2032)
- 9.2 Asia-Pacific Kidney (Renal) Fibrosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Kidney (Renal) Fibrosis Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Kidney (Renal) Fibrosis Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Kidney (Renal) Fibrosis Market Size (2021-2032)
- 10.2 South America Kidney (Renal) Fibrosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Kidney (Renal) Fibrosis Market Size by Country (2021-2026)
- 10.4 South America Kidney (Renal) Fibrosis Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Kidney (Renal) Fibrosis Market Size (2021-2032)
- 11.2 Middle East & Africa Kidney (Renal) Fibrosis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Kidney (Renal) Fibrosis Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Kidney (Renal) Fibrosis Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.1.4 Merck Kidney (Renal) Fibrosis Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.2.4 Roche Kidney (Renal) Fibrosis Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.3.4 Pfizer Kidney (Renal) Fibrosis Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 ProMetic Life-Sciences Inc.
- 12.4.1 ProMetic Life-Sciences Inc. Company Information
- 12.4.2 ProMetic Life-Sciences Inc. Business Overview
- 12.4.3 ProMetic Life-Sciences Inc. Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.4.4 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Product Portfolio
- 12.4.5 ProMetic Life-Sciences Inc. Recent Developments
- 12.5 La Jolla Pharmaceutical Company
- 12.5.1 La Jolla Pharmaceutical Company Company Information
- 12.5.2 La Jolla Pharmaceutical Company Business Overview
- 12.5.3 La Jolla Pharmaceutical Company Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.5.4 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Product Portfolio
- 12.5.5 La Jolla Pharmaceutical Company Recent Developments
- 12.6 InterMune
- 12.6.1 InterMune Company Information
- 12.6.2 InterMune Business Overview
- 12.6.3 InterMune Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.6.4 InterMune Kidney (Renal) Fibrosis Product Portfolio
- 12.6.5 InterMune Recent Developments
- 12.7 Genzyme Corporation
- 12.7.1 Genzyme Corporation Company Information
- 12.7.2 Genzyme Corporation Business Overview
- 12.7.3 Genzyme Corporation Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.7.4 Genzyme Corporation Kidney (Renal) Fibrosis Product Portfolio
- 12.7.5 Genzyme Corporation Recent Developments
- 12.8 Galectin Therapeutics
- 12.8.1 Galectin Therapeutics Company Information
- 12.8.2 Galectin Therapeutics Business Overview
- 12.8.3 Galectin Therapeutics Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.8.4 Galectin Therapeutics Kidney (Renal) Fibrosis Product Portfolio
- 12.8.5 Galectin Therapeutics Recent Developments
- 12.9 BioLine Rx Ltd
- 12.9.1 BioLine Rx Ltd Company Information
- 12.9.2 BioLine Rx Ltd Business Overview
- 12.9.3 BioLine Rx Ltd Revenue in Kidney (Renal) Fibrosis Business (2021-2026)
- 12.9.4 BioLine Rx Ltd Kidney (Renal) Fibrosis Product Portfolio
- 12.9.5 BioLine Rx Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst